Page last updated: 2024-12-10

2-(1-benzo[e]benzofuranyl)-N-[4-methoxy-3-(4-morpholinylsulfonyl)phenyl]acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're describing a molecule with a complex chemical name. Here's a breakdown of what it likely is and why it might be important in research:

**What it is:**

* **2-(1-benzo[e]benzofuranyl)-N-[4-methoxy-3-(4-morpholinylsulfonyl)phenyl]acetamide** is a synthetic organic compound.
* **Benzo[e]benzofuran:** This part refers to a specific fused ring system. Benzofuran itself is a ring structure containing a benzene ring (6-membered ring with alternating double bonds) and a furan ring (5-membered ring with an oxygen atom). The benzo[e] indicates how this system is fused onto another benzene ring.
* **Acetamide:** This is a simple amide group, a common functional group in organic chemistry.
* **N-[4-methoxy-3-(4-morpholinylsulfonyl)phenyl]:** This part describes a complex substituent attached to the nitrogen of the acetamide. Let's break it down:
* **4-methoxy:** A methoxy group (CH3O-) attached to the phenyl ring at the 4-position.
* **3-(4-morpholinylsulfonyl):** This is a longer group attached to the 3-position of the phenyl ring.
* **Morpholine:** A six-membered heterocyclic ring containing an oxygen and a nitrogen.
* **Sulfonyl:** A sulfur atom double-bonded to two oxygen atoms.

**Why it might be important in research:**

Without more specific context, it's difficult to say precisely why this compound is being researched. However, given its structure, it's likely related to:

* **Drug Discovery:** The presence of various functional groups (amides, sulfonyl, ether, etc.) suggests this compound could be a **potential drug candidate**.
* **Biological Activity:** Compounds with this type of structure often exhibit interesting biological activity (e.g., binding to proteins, enzymes, or receptors) which could be useful for treating diseases.
* **Materials Science:** This compound could be a **precursor or building block** for larger, more complex molecules used in materials development.
* **Organic Synthesis:** It might be a **synthetic intermediate** used in the preparation of other valuable compounds.

**To understand its specific research relevance, you'd need to:**

* **Know the research context:** What are the goals of the research project? What disease or problem is it addressing?
* **See the experimental details:** What tests and assays are being conducted with this compound? What biological targets or materials are being studied?

**If you have more information about the research project, please share it, and I can provide a more specific answer.**

Cross-References

ID SourceID
PubMed CID3312717
CHEMBL ID1399744
CHEBI ID114899

Synonyms (15)

Synonym
MLS000336616
smr000248228
CHEBI:114899
2-benzo[e][1]benzofuran-1-yl-n-(4-methoxy-3-morpholin-4-ylsulfonylphenyl)acetamide
HMS2559D23
MLS003912259
chembl1399744 ,
bdbm50370165
Q27196742
2-(1-benzo[e]benzofuranyl)-n-[4-methoxy-3-(4-morpholinylsulfonyl)phenyl]acetamide
Z28622906
AKOS034060346
736950-91-7
n-(4-methoxy-3-(morpholinosulfonyl)phenyl)-2-(naphtho[2,1-b]furan-1-yl)acetamide
way-621001
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphthofuran
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485341
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency13.45910.007215.758889.3584AID588342
acid sphingomyelinaseHomo sapiens (human)Potency14.125414.125424.061339.8107AID504937
ATAD5 protein, partialHomo sapiens (human)Potency29.09290.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency27.51100.000811.382244.6684AID686978; AID686979
67.9K proteinVaccinia virusPotency19.11800.00018.4406100.0000AID720579; AID720580
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency35.48130.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.78280.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency31.62280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency20.59620.00419.984825.9290AID504444
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency75.68630.425612.059128.1838AID504891
gemininHomo sapiens (human)Potency22.72650.004611.374133.4983AID624296; AID624297
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sphingomyelin phosphodiesteraseHomo sapiens (human)IC50 (µMol)14.12545.00005.30005.6000AID1357899
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
symbiont entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
symbiont entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
plasma membrane repairSphingomyelin phosphodiesteraseHomo sapiens (human)
sphingomyelin metabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
sphingomyelin catabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
signal transductionSphingomyelin phosphodiesteraseHomo sapiens (human)
nervous system developmentSphingomyelin phosphodiesteraseHomo sapiens (human)
cholesterol metabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
response to xenobiotic stimulusSphingomyelin phosphodiesteraseHomo sapiens (human)
response to virusSphingomyelin phosphodiesteraseHomo sapiens (human)
response to ionizing radiationSphingomyelin phosphodiesteraseHomo sapiens (human)
termination of signal transductionSphingomyelin phosphodiesteraseHomo sapiens (human)
response to type I interferonSphingomyelin phosphodiesteraseHomo sapiens (human)
response to tumor necrosis factorSphingomyelin phosphodiesteraseHomo sapiens (human)
cellular response to UVSphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of protein dephosphorylationSphingomyelin phosphodiesteraseHomo sapiens (human)
wound healingSphingomyelin phosphodiesteraseHomo sapiens (human)
response to cocaineSphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of apoptotic processSphingomyelin phosphodiesteraseHomo sapiens (human)
negative regulation of MAP kinase activitySphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of endocytosisSphingomyelin phosphodiesteraseHomo sapiens (human)
glycosphingolipid catabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
ceramide biosynthetic processSphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of viral entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
symbiont entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
response to interleukin-1Sphingomyelin phosphodiesteraseHomo sapiens (human)
cellular response to calcium ionSphingomyelin phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
sphingomyelin phosphodiesterase activitySphingomyelin phosphodiesteraseHomo sapiens (human)
protein bindingSphingomyelin phosphodiesteraseHomo sapiens (human)
zinc ion bindingSphingomyelin phosphodiesteraseHomo sapiens (human)
hydrolase activity, acting on glycosyl bondsSphingomyelin phosphodiesteraseHomo sapiens (human)
phosphatidylcholine phospholipase C activitySphingomyelin phosphodiesteraseHomo sapiens (human)
acid sphingomyelin phosphodiesterase activitySphingomyelin phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
extracellular spaceSphingomyelin phosphodiesteraseHomo sapiens (human)
lysosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
extracellular spaceSphingomyelin phosphodiesteraseHomo sapiens (human)
lysosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
endosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
lipid dropletSphingomyelin phosphodiesteraseHomo sapiens (human)
plasma membraneSphingomyelin phosphodiesteraseHomo sapiens (human)
endolysosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
lamellar bodySphingomyelin phosphodiesteraseHomo sapiens (human)
lysosomal lumenSphingomyelin phosphodiesteraseHomo sapiens (human)
extracellular exosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1357899Inhibition of acid sphingomyelinase in human HuH7 cell lysate using NBD-sphingomyelin as substrate after 30 mins by TLC based fluorescence assay2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of N-hydroxy-3-alkoxybenzamides as direct acid sphingomyelinase inhibitors using a ligand-based pharmacophore model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]